Filtered By:
Drug: Diovan

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
Abstract Angiotensin II receptor blockers (ARBs) are known to prevent ischemic brain damage after stroke. Natriuretic peptides, which are increased by a neprilysin inhibitor, are also reported to protect against brain damage. Therefore, we investigated the possible protective effect of valsartan (VAL) compared with LCZ696 (VAL+ neprilysin inhibitor; 1:1) after middle cerebral artery (MCA) occlusion. Eight-week-old male C57BL/6J mice were treated with VAL (3mg/kg per day) or LCZ696 (6mg/kg per day) for 2 weeks before MCA occlusion. Blood pressure and heart rate were measured by telemetry. Cerebral blood flow (CBF) ...
Source: European Journal of Pharmacology - June 6, 2015 Category: Drugs & Pharmacology Authors: Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, Higaki A, Iwanami J, Horiuchi M Tags: Eur J Pharmacol Source Type: research

Humid heat exposure induced oxidative stress and apoptosis in cardiomyocytes through the angiotensin II signaling pathway
Abstract Exposure to humid heat stress leads to the initiation of serious physiological dysfunction that may result in heat-related diseases, including heat stroke, heat cramp, heat exhaustion, and even death. Increasing evidences have shown that the humid heat stress-induced dysfunction of the cardiovascular system was accompanied with severe cardiomyocyte injury; however, the precise mechanism of heat stress-induced injury of cardiomyocyte remains unknown. In the present study, we hypothesized that humid heat stress promoted oxidative stress through the activation of angiotensin II (Ang II) in cardiomyocyte...
Source: Heart and Vessels - May 1, 2015 Category: Cardiology Source Type: research

Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
ConclusionsIn VALIANT, the risk of HF following MI was higher in women than men after adjusting for age and comorbidities, although the risk of other fatal and non‐fatal outcomes were similar. The higher long‐term risk of HF in women appears to be independent of the extent of left ventricular systolic dysfunction or remodelling compared with men.
Source: European Journal of Heart Failure - February 6, 2015 Category: Cardiology Authors: Carolyn S. P. Lam, Margaret McEntegart, Brian Claggett, Jiankang Liu, Hicham Skali, Eldrin Lewis, Lars Køber, Jean Rouleau, Eric Velazquez, Rob Califf, John J. McMurray, Marc Pfeffer, Scott Solomon Tags: Original Article Source Type: research

Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.
Abstract The effects of levosimendan on cerebrovascular lesions and mortality were investigated in models of primary and secondary stroke. We aimed to determine whether the effects of levosimendan are comparable to and/or cumulative with those of valsartan, and to investigate whether levosimendan-induced vasodilation has a role in its effects on stroke. In a primary stroke Dahl/Rapp rat model, mortality rates were 70% and 5% for vehicle and levosimendan, respectively. Both stroke incidence (85% vs. 10%, P<0.001) and stroke-associated behavioral deficits (7-point neuroscore: 4.59 vs. 5.96, P<0.001) were worse...
Source: European Journal of Pharmacology - January 29, 2015 Category: Drugs & Pharmacology Authors: Levijoki J, Kivikko M, Pollesello P, Sallinen J, Hyttilä-Hopponen M, Kuoppamäki M, Haasio K, Gröhn O, Miettinen R, Puoliväli J, Tähtivaara L, Yrjänheikki J, Haapalinna A Tags: Eur J Pharmacol Source Type: research

Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open‐label, blinded–end‐point trial
ConclusionsEarly reduction of BP with valsartan did not reduce death or dependency and major vascular events at 90 days, but increased the risk of END.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Mi Sun Oh, Kyung‐Ho Yu, Keun‐Sik Hong, Dong‐Wha Kang, Jong‐Moo Park, Hee‐Joon Bae, Jaseong Koo, Juneyoung Lee, Byung‐Chul Lee, Tags: Research Source Type: research

A Cost Utility Analysis of Amlodipine Compared with Angiotensin II Receptor Blockers in Preventing Stroke and Myocardial Infarction Among Hypertension Patients in the Philippines
Hypertension represents a major health problem, affecting more than 21% of adults in the Philippines. Amlodipine, a calcium channel blocker, is considered to have better tolerance and effectiveness than other classes of antihypertensive treatments. Limited studies have examined the cost-effectiveness of Amlodipine in the Philippines. The purpose of this study was to compare the costs and effectiveness associated with Amlodipine and Angiotensin II Receptor Blockers (Valsartan) in preventing stroke and myocardial infarction (MI) among Filipino hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: G Encelan-Brizuela, K.Y. Lin, L. Liu Source Type: research

A Cost-Utility Analysis of Calcium Channel Blockers (Ccbs) Compared with Angiotensin II Receptor Blockers (Arbs) In Preventing Stroke And Myocardial Infarction Among Hypertension Patients In The Taiwan
Hypertension is a major risk factor for stroke and myocardial infarction (MI), which imposes a substantial burden on patients, caregivers, and society. Despite the high financial burden, limited studies have examined the cost-effectiveness of hypertension treatments in Taiwan. This cost utility analysis was conducted to determine the costs and quality-adjusted life years (QALYs) associated with amlodipine (CCB) and valsartan (ARB) in preventing stroke and MI among Taiwanese hypertension patients.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: C.H. Fang, K.Y. Lin, Y.C. Huang, L. Liu Source Type: research

Comment NAVIGATOR: physical activity for cardiovascular health?
In The Lancet, Thomas Yates and colleagues report new findings from the NAVIGATOR trial, a multicentre, international, randomised, placebo-controlled trial that examined the effect of nateglinide, valsartan, or both, on cardiovascular events in patients with impaired glucose tolerance and either existing cardiovascular disease or at least one additional risk factor. The results of this cohort analysis of the association between daily ambulatory activity, as assessed by pedometer, and a composite of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke, show a graded and independent inverse...
Source: LANCET - March 21, 2014 Category: Journals (General) Authors: Giuseppe Pugliese, Stefano Balducci Tags: Comment Source Type: research

Walking reduces heart disease in people at risk
Conclusion This study of adults at high risk of type 2 diabetes and heart disease has found that every 2,000 steps they normally took each day was associated with a 10% lower risk of a cardiovascular event. And 12 months later, each extra 2,000 steps per day people did beyond their original number of steps was associated with an additional 8% difference in the cardiovascular event rate. This large study recruited participants from around the world and the researchers adjusted for a number of potential confounders. However, the study had a number of limitations, including: A large amount of information on the number of s...
Source: NHS News Feed - December 23, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news

“Fere libenter homines id quod volunt credunt”: Apprehension for the stroke reduction in the KYOTO HEART Study on the basis of meta-regression from the evidence
“Fere libenter homines id quod volunt credunt (Men willingly believe what they wish).”De Bello Gallico, Book III, Chapter 18 The KYOTO HEART Study [NCT00149227] was designed to examine whether valsartan (angiotensin-receptor blocker [ARB]) added to the conventional anti-hypertensive treatment influences the cardiovascular events in the high-risk Japanese patients with uncontrolled hypertension. The authors used the Prospective, Randomized, Open-labeled, Blinded Endpoints (PROBE) , two-arm parallel treatment group comparison study design with a response-dependent dose titration scheme. Main results of the KYOTO HEART S...
Source: International Journal of Cardiology - December 16, 2013 Category: Cardiology Authors: Hisato Takagi, Takuya Umemoto, for the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group Tags: Editorials Source Type: research

Protective effect of valsartan for stroke in Japanese subjects: an analysis of Jikei Heart Study: Retraction
No abstract available
Source: Journal of Hypertension - October 8, 2013 Category: Cardiology Tags: Retractions Source Type: research

Effects of Valsartan Versus Amlodipine in Diabetic Hypertensive Patients With or Without Previous Cardiovascular Disease
In conclusion, the ARB- and the CCB-based treatments exerted similar protective effects of CVD events regardless of the presence of previous CVD. For stroke events, the ARB may have more protective effects than the CCB in diabetic hypertensive patients with previous CVD.
Source: The American Journal of Cardiology - September 16, 2013 Category: Cardiology Authors: Kentaro Yamashita, Takahisa Kondo, Takashi Muramatsu, Kunihiro Matsushita, Takanori Nagahiro, Kengo Maeda, Satoshi Shintani, Toyoaki Murohara Tags: Systemic Hypertension Source Type: research

Predictors of Stroke in Patients With Impaired Glucose Tolerance: Results From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial Brief Reports
Conclusions— The most powerful predictors of stroke in patients with impaired glucose tolerance included a combination of established risk factors and novel variables, such as previous venous thromboembolism and elevated waist circumference, allowing moderately effective identification of high-risk individuals.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Preiss, D., Giles, T. D., Thomas, L. E., Sun, J.-L., Haffner, S. M., Holman, R. R., Standl, E., Mazzone, T., Rutten, G. E., Tognoni, G., Chiang, F.-T., McMurray, J. J. V., Califf, R. M. Tags: Cerebrovascular disease/stroke, Risk Factors, Glucose intolerance Brief Reports Source Type: research

Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure...
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news

Two ARBs Lower Risk of CVD Complications in DiabeticsTwo ARBs Lower Risk of CVD Complications in Diabetics
Compared with irbesartan, the use of telmisartan and valsartan lowered the risk of hospital admission for MI, stroke, or heart failure by 15% and 14%, respectively. The reduction was driven primarily by a reduction in the risk of heart-failure hospitalizations. Heartwire
Source: Medscape Today Headlines - July 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news